A Randomized, Double-blind Phase 2 Study of Itacitinib in Combination With Erlotinib Versus Erlotinib Alone in Subjects With Stage IIIB/ IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 18 Jun 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Itacitinib (Primary) ; Erlotinib
Indications Non-small cell lung cancer
Focus Adverse reactions; Proof of concept; Therapeutic Use
Sponsors Incyte Corporation

Most Recent Events

31 Aug 2018 Biomarkers information updated
16 Nov 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
30 Oct 2014 Planned initiation date changed from 1 Jun 2014 to 31 Dec 2014 according to media release.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight